A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain

Inclusion Criteria:

• Have a visual analog scale (VAS) pain value ≥40 and <95 during screening.

• Have a history of daily pain for at least 12 weeks based on participant report ormedical history.

• Have a body mass index <40 kilograms per meter squared (kg/m²) (inclusive).

• Are willing to maintain a consistent regimen of any ongoing nonpharmacologicpain-relieving therapies (for example, physical therapy) and will not start any newnonpharmacologic pain-relieving therapies during study participation.

• Are willing to discontinue all medications taken for chronic pain conditions for theduration of the study.

• Have a history of low back pain for at least 3 months located between the 12ththoracic vertebra and the lower gluteal folds, with or without radiation.

• Have a history of low back pain as classified by the Quebec Task Force Category 1through 3.

• Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less thanor equal to 10 at time of screening.

• Are men, or women able to abide by reproductive and contraceptive requirements.

Exclusion Criteria:

• Have a seizure disorder, history of seizure (other than remote history of childhoodfebrile seizure), or a condition that would place the participant at increased riskof seizure, such as head injury (for example, skull fracture, cerebral contusion,concussion, or trauma resulting in prolonged unconsciousness), intracranial neoplasmor hemorrhage.

• Have had a procedure within the past 6 months intended to produce permanent sensoryloss in the target area of interest (for example, ablation techniques).

• Have surgery planned during the study for any reason, related or not to the diseasestate under evaluation.

• Have, in the judgment of the investigator, an acute, serious, or unstable medicalcondition or a history or presence of any other medical illness that would precludestudy participation.

• Have had cancer within 2 years of baseline, except for cutaneous basal cell orsquamous cell carcinoma resolved by excision.

• Have a substance use disorder as defined by the Diagnostic and Statistical Manual ofMental Disorders (5th edition; DSM-5; American Psychiatric Association).

• Have a positive human immunodeficiency virus (HIV) test result at screening.

• Are, in the judgment of the investigator, actively suicidal and therefore deemed tobe at significant risk for suicide.

• Have an intolerance to acetaminophen or paracetamol or any of its excipients.

• Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2years prior to screening.

• Have used a therapeutic injection (botulinum toxin or corticosteroids) in the 3months prior to starting the washout period.

• Have history of or current compression fracture.

• Have had a recent major trauma (within 6 months of baseline).

• Are pregnant or breastfeeding.

• Have known history of gastric or duodenal ulcers.

• Have known history of inflammatory bowel disease (including ulcerative colitis orCrohn's disease).